Moderna's Stock Target Rises as Biotech Sector Gains Momentum

Moderna, Inc. (NASDAQ:MRNA) emerges as one of the top 10 performing U.S. stocks in June 2026. RBC Capital raised its price target to $45 from $38 on July 7, maintaining a 'Sector Perform' rating amid a broader Q2 earnings preview for the biotech sector. The firm highlighted strong data-driven momentum and improved FDA flexibility as key drivers. Meanwhile, Piper Sandler increased its target to $77 from $69 on June 26, retaining an 'Overweight' stance.

At its June 25 Science Day event, Moderna emphasized balancing near-term growth with long-term innovation through four approved products, infectious disease launches, and late-stage pipeline opportunities like investigational intismeran autogene therapy. The company also showcased its Scientific Intelligence Engine, integrating AI, machine learning, and automation to accelerate R&D processes.

■RBC Capital raises Moderna target to $45, citing sector momentum.

■Piper Sandler increases target to $77, underscores strong fundamentals.

■Moderna leverages AI-driven platforms to enhance operational efficiency.

■Regulatory clarity and M&A activity fuel biotech sector optimism.

Markets view this upward trajectory as a reflection of evolving regulatory frameworks and strategic tech integration. Moderna's revised targets signal renewed investor confidence in biotech innovation amid shifting global trade policies.